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Previewsencoding of events into memory (Unca-
pher and Wagner, 2009).
Nelson et al.’s findings are part of a
rising tide of data documenting a mosaic
of distinct areas in human parietal cortex,
which vary in their local functional proper-
ties as well as their global connectivity.
The authors’ efforts to parcellate parietal
cortex complement related efforts to
delineate occipito-temporal visual areas,
wherein distinct areas are thought to
have unique cytoarchitecture, anatomical
connectivity, and functional properties.
Continued examination of parietal hetero-
geneity using convergent techniques pro-
mises to ultimately reveal a fine-grained
human parietal functional map, which
will prove invaluable for understanding
the neural bases of many aspects of
cognition, from attention to memory and
beyond.8 Neuron 67, July 15, 2010 ª2010 Elsevier InREFERENCES
Cabeza, R., Ciaramelli, E., Olson, I.R., and
Moscovitch, M. (2008). Nat. Rev. Neurosci. 9,
613–625.
Caspers, S., Eickhoff, S.B., Geyer, S., Scheper-
jans, F., Mohlberg, H., Zilles, K., and Amunts, K.
(2008). Brain Struct. Funct. 212, 481–495.
Corbetta, M., Patel, G., and Shulman, G.L. (2008).
Neuron 58, 306–324.
Fox, M.D., and Raichle, M.E. (2007). Nat. Rev.
Neurosci. 8, 700–711.
Hutchinson, J.B., Uncapher, M.R., and Wagner,
A.D. (2009). Learn. Mem. 16, 343–356.
Konen, C.S., and Kastner, S. (2008). J. Neurosci.
28, 8361–8375.
Nelson, S.M., Cohen, A.L., Power, J.D., Wig, G.S.,
Miezin, F.M., Wheeler, M.E., Velanova, K.,
Donaldson, D.I., Phillips, J.S., Schlaggar, B.L.,
and Petersen, S.E. (2010). Neuron 67, this issue,
156–170.c.Scheperjans, F., Eickhoff, S.B., Homke, L.,
Mohlberg, H., Hermann, K., Amunts, K., and Zilles,
K. (2008). Cereb. Cortex 18, 2141–2157.
Uddin, L.Q., Supekar, K., Amin, H., Rykhlevskaia,
E., Nguyen, D.A., Greicius, M.D., and Menon, V.
(2010). Cereb. Cortex, in press. Published online
February 12, 2010. 10.1093/cercor/bhq011.
Uncapher, M.R., and Wagner, A.D. (2009). Neuro-
biol. Learn. Mem. 91, 139–154.
Vilberg, K.L., and Rugg, M.D. (2008). Neuropsy-
chologia 46, 1787–1799.
Vincent, J.L., Snyder, A.Z., Fox, M.D., Shannon,
B.J., Andrews, J.R., Raichle, M.E., and Buckner,
R.L. (2006). J. Neurophysiol. 96, 3517–3531.
Vincent, J.L., Kahn, I., Snyder, A.Z., Raichle, M.E.,
and Buckner, R.L. (2008). J. Neurophysiol. 100,
3328–3342.
Wagner, A.D., Shannon, B.J., Kahn, I., and
Buckner, R.L. (2005). Trends Cogn. Sci. 9, 445–
453.
Wheeler, M.E., and Buckner, R.L. (2004).
Neuroimage 21, 1337–1349.Genome Variation and Complexity
in the Autism SpectrumL.N. van de Lagemaat1 and Seth G.N. Grant1,*
1Genes to Cognition Programme, Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK
*Correspondence: sg3@sanger.ac.uk
DOI 10.1016/j.neuron.2010.06.026
A large international consortium reports inNature on the diversity of genomic changes in families with autism
spectrum disorders. Inherited and de novo mutations affecting many genes were discovered implicating
disruption to postsynaptic and cellular signaling processes.Autism spectrum disorders (ASDs) em-
brace a combination of behavioral pheno-
types impacting on cognitive, social, and
motor functions. The genetic basis of
ASD, originally revealed in twin and family
studies, is now being investigated on
a genome-wide level using recent techno-
logical advances, resulting in the dis-
covery of a multiplicity of putative driver
mutations in neuronal and neurodevelop-
mental genes, including postsynaptic
genes (Pinto et al., 2010 [a recent issue
of Nature]). Understanding how this com-
plex genetic etiology disrupts biochem-
ical mechanisms and influences the
spectrum of behavioral phenotypes inindividuals may lead to new therapeutic
avenues and insights into the molecular
basis of human social interactions.
With the inexorable progress toward
whole genome sequencing, mutations
ranging in size from a single nucleotide
to deletions and insertions of contiguous
regions will be measured in each and
every gene for all diseases. Many rare
diseases of the nervous system are
caused by a mutation in single genes,
and there are ‘‘complex’’ diseases that
have their basis in mutations affecting
many genes. Prominent among these
complex diseases are ASD, schizo-
phrenia, and bipolar disease (Carroll andOwen, 2009). While it is only a matter of
time before we have a definitive descrip-
tion of the genomic variation in ASD indi-
viduals using whole genome sequencing,
an international consortium has reported
the genomic variation at a lower resolution
in individuals and families with ASD (Pinto
et al., 2010). This report, building on
earlier studies, provides new evidence
that changes in the function of many
genes, arising by rare inherited and de
novo mutations, underlie the behavioral
phenotypes of ASD.
The study surveyed the genome for
deletions or insertions (extra copies of
genomic DNA) greater than 30 kb in size
Neuron
Previewsand asked if ASD cases were different
to controls. These are known as copy
number variants (CNV) and represent
a type of chromosomal rearrangement.
Since the 1920s, chromosomal architec-
ture was visualized using DNA staining
and microscopy, giving rise to the disci-
pline of cytogenetics, an approach that
led to the discovery of the genetic basis of
human diseases such as chronic myelog-
enous leukemia and Down’s syndrome.
Refinements in techniques including fluo-
rescence in situ hybridization (FISH) and
oligonucleotide hybridization improved
the resolution of cytogenetic assays from
tens of megabases to the current levels of
20 nucleotides. Unlike FISH, oligonucle-
otide microarrays allow rapid, efficient,
and unbiased genome-wide assays for
DNA variation and have fuelled high-reso-
lution linkage and association scans
seeking to find the mutational basis of
schizophrenia, bipolar disorder, and ASD
(Craddock et al., 2009; Psychiatric GWAS
Consortium Coordinating Committee
et al., 2009). The present study used
commercial microarrays with one million
synthetic oligonucleotides designed to
survey all genes and chromosomal
regions with representative probes.
Genomic DNA from cases and controls
was hybridized to the microarrays, and
the intensity of the hybridization signal
provided a quantification of the number
of DNA copies in that part of the genome.
Why are CNVs good candidates for
pathogenic variants? While polymor-
phisms in single nucleotides can alter
protein structure and function, or influence
gene regulation, the number of nucleotides
affected by CNVs is much larger (Cheng
et al., 2005). CNVs are more likely to affect
genes, either by insertions or deletions that
interrupt protein coding regions, or change
gene dosage (and thus levels of mRNA)
by duplicating or deleting a copy of the
gene. It is worth noting the similarity
between CNVs and the favorite tools of
the mouse geneticists—transgenic inser-
tion or knockout deletion of whole
genes—as both change gene dosage.
Moreover, this emphasizes the relevance
of mouse models as a tool to verify the
functional significance of human CNVs.
Before considering how CNVs might
result in disease, it is important to
remember that the genome is dynamic
and constantly evolving, generating varia-tion and diversity, much of which may be
without phenotypic consequences. The
extent of this diversity was revealed by
a catalog of 11,700 CNVs found within
normal populations measured using
ultra-high density oligonucleotide arrays
(Conrad et al., 2010). Investigating 3432
commonCNV regions, a large-scale study
of eight common diseases (including
bipolar disorder) concluded that common
CNVs were unlikely to account for much
disease (Wellcome Trust Case Control
Consortium et al., 2010). This leaves
open the possibility that rare CNVs are
more pathogenic but also underlines the
challenge faced in establishing the func-
tional significance of a CNV.
Pinto and colleagues (2010) have used
a family linkage study design to search
the genome of ASD cases for gene
disruptions by CNVs that segregate with
ASD. They specifically examined those
CNVs R30 kb in length that were rare
(<1% of all individuals) and overlapped
protein coding genes. They examined
996 ASD cases including 876 in parent-
offspring trios, thus distinguishing in-
herited from de novo CNVs. CNVs in these
trios were also compared with CNVs found
in another 1287 normal controls. The
average number of genes intersected by
CNVs in each control individual was 3.6,
giving an indication of the normal genic
burden of CNVs. Their first finding was
that ASD cases had 19% more affected
genes (4.3 genes) than controls. This was
statistically significant and stronger for
deletions than insertions, suggesting that
loss of function of genes is more frequent
in ASD. Next, they asked whether these
CNVs arose as inherited or de novo
events; they found in their trios that 5.7%
of cases had a de novo event, reinforcing
earlier reports showing de novo mutations
arise in complex neuropsychiatric disor-
ders (Glessner et al., 2009). This is an inter-
esting and as yet unexplained phenom-
enon, which could reflect differences in
mutation rate or genomic stability.
A fundamental limitation on analysis of
rare and de novo variants is the rarity of
these events. For example, SHANK2,
SynGAP, and DLGAP2 involvements in
ASD were only supported by variants in
one or two cases each. Despite the lack
of formal statistical significance, however,
the authors cite the fact that mutations in
these proteins, their interacting partners,Neuor their paralogs have been implicated
before in ASD or mental retardation (Du-
rand et al., 2007; Hamdan et al., 2009;
Romorini et al., 2004), which helps to build
the case for their relevance. As shown in
Figure 1, they highlight SHANK2, Syn-
GAP1, and DLGAP2, which interact in
postsynaptic complexes with MAGUK
(membrane associated guanylate kinase)
proteins (PSD-95/DLG4, SAP102/DLG3,
PSD-93/DLG2). MAGUKs also bind gluta-
mate receptors (NMDA, AMPA, metabo-
tropic) and Neuroligins, which in turn bind
Neurexins, among other proteins. De novo
CNVs disrupting Neurexin1 exons were de-
tected in four ASD cases. Several of these
additional interacting proteins were earlier
implicated in other human cognitive disor-
ders: mental retardation (SAP102/DLG3;
SynGAP), ASD (SHANK3), and schizo-
phrenia (PSD93/DLG2, DLGAP1). Addi-
tional support for the functional relevance
of CNVs in these proteins comes from the
observation that cognition is altered in
knockout mouse models of SynGAP,
SHANK1, and DLGAP3.
One of the attractions of a model where
rare mutations affect different proteins in
the same multiprotein complex is that
although a particular gene may be disrup-
ted by only one CNV in a whole study,
and thus fail to reach statistical signifi-
cance, independent mutations in function-
ally interacting subsets of brain proteins
may yet point the way to a biochemical
mechanism for the disease. In addition,
varying phenotypes due to mutations of
different interacting proteins can help
define the genetic underpinnings of the
‘‘spectrum’’ of related phenotypes. A
detailed study of the specific endopheno-
types of individuals with the mutations in
SynGAP, SHANK, and DLGAP2 and other
interacting proteins may shed light on the
molecular basis of these ASD endopheno-
types and their relationship to schizo-
phrenia and other diseases.
Although there is accumulating and
compelling evidence that ASDs involve
postsynaptic complexes, inspection of
genic content of other de novo events
reveals putative disruption of proteins
found in the nucleus: NFIA is a transcrip-
tional activator; CHD2 is a sequence-
selective DNA binding helicase; RBL2
maintains chromatin configuration. It
may be that ASD involves both nuclear
and synaptic pathology due to someron 67, July 15, 2010 ª2010 Elsevier Inc. 9
Figure 1.
Interacting synaptic proteins disrupted by CNVs in Pinto (colored) and/or
implicated in other cognitive disorders in humans (black star) and mouse
(red star).
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between these proteins.
Another approach to the
data was an enrichment anal-
ysis of rare variants with
respect to several short gene
lists constructed from the stu-
dies of others. This approach
was useful, because it groups
variants that by themselves
are insignificantly associated
with the disease and answer
the question: are these data
in agreement with those of
others? One such list the
authors used was an ‘‘autism
implicated’’ list containing
the 46 best candidate regions
so far identified by others:
4.3% of cases in the present
study had rare CNVs impact-
ing genes in this list, com-
pared to 2.3% of controls.
Even though this may seem
like a small proportion of thecases, it may be an underestimate
resulting from limitations in the microarray
method, which future resequencing of
these genes will clarify.
In an attempt to find known biochem-
ical pathways or processes targeted by
the CNVs, a gene set enrichment analysis
was also performed using gene sets
compiled from the Gene Ontology, KEGG
pathways, and other sources. Among
3493 gene-sets tested, only 76 exhibited
enrichment, and then only in deletions,
suggesting as before that deletions are
more likely to cause functional disruption
than insertions. Enriched sets included
kinase activity, GTPase/Ras signaling, cell
proliferation, cell projection, and motility,
which generally point to signal transduction
and growth related processes. Interest-
ingly, although the tested gene sets
includedneurotransmitters and their recep-
tors, these were not enriched by the ASD
CNVs, suggesting ASD is less a disorder
of neurotransmitters and more a disorder
of intracellular signaling processes.
Complex genetic disorders of the
nervous system pose a range of special
problems, some of which are illustrated
by this study, and we believe will require
new approaches. The fact that many
genomic changes underpin ASD, schizo-
phrenia, bipolar, and other complex
genetic disorders, illustrates the need for10 Neuron 67, July 15, 2010 ª2010 Elsevier Iresearch strategies that emphasize the
function of sets of genes. The involvement
of sets of genes in biochemical machines,
such as postsynaptic signaling complexes
(Ferna´ndez et al., 2009) or networks
(Pocklington et al., 2006) may reduce the
statistical complexity of these investiga-
tions and offer clues to the underlying
etiology of these diseases. How these
networks are altered by the range of
mutations could be tested with suitable
model systems, which will always need
to include behavioral models since the
diseases manifest as social, cognitive,
and motoric changes. In this regard, we
see a need for programs of systematic
analysis of mouse models in specific and
relevant psychological tests that are
coordinated with human genetic studies
and genome sequencing. As indicated
by Pinto et al. (2010), it will be essential
to ask if specific components within the
spectrum of autism phenotypes map
onto specific genotypes; an endeavor
that will require coordinated efforts of
clinicians and geneticists. The scale of
the genetic complexity, the need to coor-
dinate human genetic studies with mouse
genetic models and the need to coordi-
nate clinical studies with genome
sequencing suggests that ASD, as well as
schizophrenia, bipolar, and other com-
plex diseases, would greatly benefit fromnc.coordinated large scale inter-
national research programs.
REFERENCES
Carroll, L.S., and Owen, M.J.
(2009). Genome Med. 1, 102.
Cheng, Z., Ventura, M., She, X.,
Khaitovich, P., Graves, T., Osoe-
gawa, K., Church, D., DeJong, P.,
Wilson, R.K., Pa¨a¨bo, S., et al.
(2005). Nature 437, 88–93.
Conrad, D.F., Pinto, D., Redon, R.,
Feuk, L., Gokcumen, O., Zhang,
Y., Aerts, J., Andrews, T.D., Barnes,
C., Campbell, P., et al; Wellcome
Trust Case Control Consortium.
(2010). Nature 464, 704–712.
Craddock, N., Kendler, K., Neale,
M., Nurnberger, J., Purcell, S., Riet-
schel, M., Perlis, R., Santangelo,
S.L., Schulze, T.G., Schulze, T.,
et al; Cross-Disorder Phenotype
Group of the Psychiatric GWAS
Consortium. (2009). Br. J. Psychi-
atry 195, 97–99.
Durand, C.M., Betancur, C., Boeck-
ers, T.M., Bockmann, J., Chaste, P.,
Fauchereau, F., Nygren, G., Ras-tam, M., Gillberg, I.C., Anckarsa¨ter, H., et al.
(2007). Nat. Genet. 39, 25–27.
Ferna´ndez, E., Collins, M.O., Uren, R.T.,
Kopanitsa, M.V., Komiyama, N.H., Croning,
M.D., Zografos, L., Armstrong, J.D., Choudhary,
J.S., and Grant, S.G. (2009). Mol. Syst. Biol. 5,
269.
Glessner, J.T., Wang, K., Cai, G., Korvatska, O.,
Kim, C.E., Wood, S., Zhang, H., Estes, A., Brune,
C.W., Bradfield, J.P., et al. (2009). Nature 459,
569–573.
Hamdan, F.F., Gauthier, J., Spiegelman, D.,
Noreau, A., Yang, Y., Pellerin, S., Dobrzeniecka,
S., Coˆte´, M., Perreau-Linck, E., Perreault-Linck,
E., et al; Synapse to Disease Group. (2009). N.
Engl. J. Med. 360, 599–605.
Pinto, D., Pagnamenta, A.T., Klei, L., Anney, R.,
Merico, D., Regan, R., Conroy, J., Magalhaes,
T.R., Correia, C., Abrahams, B.S., et al. (2010).
Nature, in press. Published online June 9, 2010.
10.1038/nature09146.
Pocklington, A.J., Cumiskey, M., Armstrong, J.D.,
and Grant, S.G. (2006). Mol. Syst. Biol., 2006,
0023.
Psychiatric GWAS Consortium Coordinating
Committee, Cichon, S., Craddock, N., Daly, M.,
Faraone, S.V., Gejman, P.V., Kelsoe, J., Lehner,
T., Levinson, D.F., Moran, A., Sklar, P., and Sul-
livan, P.F. (2009). Am. J. Psychiatry 166,
540–556.
Romorini, S., Piccoli, G., Jiang, M., Grossano, P.,
Tonna, N., Passafaro, M., Zhang, M., and Sala, C.
(2004). J. Neurosci. 24, 9391–9404.
Wellcome Trust Case Control Consortium;
Craddock, N., Hurles, M.E., Cardin, N., Pearson,
R.D., Plagnol, V., Robson, S., Vukcevic, D.,
Barnes, C., Conrad, D.F., Giannoulatou, E., et al.
(2010). Nature 464, 713–720.
